Anti TNF-α drugs etanercept therapy of patients in the first 6 months of treatment significantly increased the risk of serious infection, the most common adverse events are nasopharyngitis (15%) and upper respiratory tract infection (6%), the AS patients received etanercept treatment should be done before the tuberculosis screening, infection, malignancy, and demyelinating disease prevention measures.[14]. This evidence concerns the gene TNF and nasopharyngitis.